🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Migraine Disease

Neuro-Complex & Multi Supplements for Migraine Prevention NCT07015411NA1 site📍 Mechelen Benfida, a department of Handi-Move · Tests: Neuro-Complex and Multi Dietary Intervention for Migraine Relief NCT07360405NA1 site📍 Washington D.C. American University · Tests: Dietary training Treatment of Meniere's Disease With Migraine Medications NCT05582837Phase 41 site📍 Orange University of California, Irvine · Tests: nortriptyline + topiramate i-NEED: NEw migrainE Drugs Database NCT07103694n/a2 sites📍 Milan📍 Rome IRCCS San Raffaele Roma · Tests: anti-CGRP monoclonal antibodies, gepants, combination of sumatriptan and naproxen, ditan The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study) NCT06628921n/a1 site📍 Roma University of Florence · Tests: Eptinezumab 100 or 300 mg ev Aimovig Pregnancy Exposure Registry NCT06150781n/a1 site📍 Durham Amgen · Tests: erenumab-aooe Combined Effects of Green Light and Transcranial Direct Current Stimulation in Migraine Patients. NCT06943625NA2 sites📍 Rawalpindi📍 Rawalpindi Riphah International University · Tests: tDCS, Green light, medicine Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine NCT07159750n/a26 sites📍 Miami📍 Buenos Aires📍 Santiago Hospital Universitari Vall d'Hebron Research Institute · Tests: CGRP antibody or gepant Gepant treAtments: EffectIveNess and tolERability (GAINER) NCT05903027n/a2 sites📍 Florence📍 Pavia University of Florence · Tests: Rimegepant 75 MG Disintegrating Oral Tablet Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications NCT06401642Phase 41 site📍 Phoenix Mayo Clinic · Tests: Zavegepant Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine NCT04743141Phase 3124 sites📍 Scottsdale📍 Tempe📍 Anaheim Pfizer · Tests: Rimegepant (PF-07899801) Aerobic Exercise and Its Impact on Sensory, Musculoskeletal, and Psychosocial Aspects in Migraine NCT06716489NA1 site📍 Ribeirão Preto University of Sao Paulo · Tests: Supervised Aerobic Exercise plus Pain Neuroscience Education, Physical Activity Recommendations Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients NCT07646613Phase 220 sites📍 Phoenix📍 Lemon Grove📍 Walnut Creek Aspeya, Inc. · Tests: ASY202, Placebo International Headache Registry Study NCT05418218n/a1 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine NCT07652034n/a1 site📍 Tacoma Cortex Neurovascular · Tests: Middle Meningeal Artery Embolization VICO-trial: Video Consultations in the Follow-up of Children With Functional Abdominal Pain Disorders NCT06665867NA1 site📍 Amsterdam Academisch Medisch Centrum - Universiteit van Amsterdam (AM… · Tests: Video consultation, Face-to-face consultation Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial NCT05337033Phase 23 sites📍 Vancouver📍 Halifax📍 Toronto University of Manitoba · Tests: MPL-001 Treatment of Episodic Migraine With AURICular Neuromodulation NCT06623188NA3 sites📍 Marseille📍 Marseille📍 Marseille Hôpital Européen Marseille · Tests: Auricular neuromodulation, Sham auricular neuromodulation Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US NCT07301008Phase 41 site📍 McLean Medstar Health Research Institute · Tests: Rimegepant 75 MG Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults NCT07304518Phase 21 site📍 Beijing Sichuan Purity Pharmaceutical Technology Co., Ltd. · Tests: PRT-064040 nasal spray, Placebo Tai Chi and Acupuncture on Migraine Attack Prevention and Brain White Matter Changes NCT06967909NA1 site📍 Hung Hom The Hong Kong Polytechnic University · Tests: Tai Chi training, Acupuncture A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years NCT06810505Phase 366 sites📍 Huntsville📍 Fayetteville📍 Little Rock AbbVie · Tests: Atogepant, Placebo for Atogepant Randomized Study in Children and Adolescents With Migraine: Acute Treatment NCT04649242Phase 3246 sites📍 Birmingham📍 Scottsdale📍 Tempe Pfizer · Tests: Rimegepant/BHV3000, Matching placebo Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Cervicogenic Headache NCT07347730NA1 site📍 Beijing Beijing Tiantan Hospital · Tests: MTrPs injection, C2 dorsal root ganglion blocks Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP NCT06584409NA1 site📍 Taichung Taichung Veterans General Hospital · Tests: Laser Pen, Observation Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine NCT07354126NA1 site📍 Lahore Muhammad Aamir Latif · Tests: Flunarizine, Propranolol Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA) NCT07347041NA1 site📍 Beijing Beijing Tiantan Hospital · Tests: Joint Cavity Injection, MTrPs Injection Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents NCT07267819n/a1 site📍 Bethesda Uniformed Services University of the Health Sciences · Tests: Xeomin (incobotulinumtoxinA) Light Exposure, Migraine Outcomes, and Sleep Quality NCT07476053NA1 site📍 Tempe Arizona State University · Tests: Ambient Lighting Condition Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine NCT06603558n/a36 sites📍 Busan📍 Busan📍 Busan AbbVie · Tests: Atogepant
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy